RecruitingPhase 4NCT07176689

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Studying Desmoid tumor

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: SpringWorks Therapeutics, Inc.
Principal Investigator: Winette van der Graff, MD
The Netherlands Cancer Institute
Intervention: Nirogacestat(drug)
Enrollment: 50 enrolled
Eligibility: 18-40 years · FEMALE
Timeline: 2025 – 2031

Study locations (19)

Cliniques Universitaires Saint-Luc (CUSL), Brussels, Belgium
Universitätsklinikum Mannheim, Mannheim Cancer Center, Mannheim, Germany
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" IRCCS IRST. S.r.l., Meldola, Forli-Cesena, Italy
Fondazione del Piemonte per l'Oncologia Istituto di Candiolo IRCCS, Candiolo, Torino, Italy
IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
Istituto Nazionale Tumori I.R.C.C.S- Fondazione G. Pascale, Naples, Italy
Fondazione Policlinico Unversitario Campus Bio-Medico di Roma, Roma, Italy
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL), Amsterdam, Netherlands
LUMC, Leiden, Netherlands
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hospital General Universitario Gregorio Maranon, Madrid, Spain
Hospital Universitario Jimenez Diaz, Madrid, Spain
Hospital Universitario La Paz, Madrid, Spain
Hospital Universitario y Politecnico La Fe, Valencia, Spain
Hospital Universitario Miguel Servet, Zaragoza, Spain
+4 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07176689 on ClinicalTrials.gov

Other trials for Desmoid tumor

Additional recruiting or active studies for the same condition.

See all trials for Desmoid tumor →

← Back to all trials